Submit a Manuscript to the Journal
Infection and Drug Resistance
For an Article Collection on
Antiviral Drugs and Resistance to RNA Viruses
Manuscript deadline
Article Collection Guest Advisor(s)
Prof. Matloob Husain,
University iof Otago, Dunedin, New Zealand
Matloob.husain@otago.ac.nz
Benefits of Publishing in an Article Collection
An Article Collection is an opportunity for your research to reach the right audience. Bringing together the work of the global research community, Collections provide readers with a central place to find the latest research on emerging and important topics. They have been found to increase the discoverability and visibility of each article, as well as article-level citations.
Antiviral Drugs and Resistance to RNA Viruses
The existing and newly emerged viruses cause acute, persistent (latent and chronic) and transformative infections in humans that cause various viral diseases. These diseases impose a significant burden on global public health. The antiviral drugs have been approved and are available to reduce the burden of diseases caused by some existing human viruses. In addition, antiviral drugs are the first line of defence against novel viruses emerging in the human population and causing viral disease outbreaks and pandemics. Broadly, antiviral drugs are of two types: host-directed and virus-directed, which target the host components and viral components, respectively, critically involved in virus life cycle.
Antiviral drugs are available against only a few human viruses, e.g., HIV, Hepatitis B virus, Hepatitis C virus, Influenza virus, Herpesvirus, Sars coronavirus-2. Furthermore, the virus-directed antiviral drugs against RNA viruses, like HIV, Influenza, Hepatitis C, and Sars coronavirus-2 lose their efficacy quickly and eventually become obsolete due to these viruses acquiring drug-resistant mutations in the targeted viral components. One of the reasons for acquiring such quick resistance is the lack of 3’-5’ proof reading capability in viral RNA-dependent RNA polymerase. Therefore, there is an ongoing need to continuously monitor and improve the efficacy of existing virus-directed drugs as well as develop new drugs against RNA viruses. In addition, there is a need to delineate RNA virus-host cell interactions to identify novel host targets to develop host-directed antiviral drugs against RNA viruses. An advantage of the latter is that viruses are slow in acquiring the resistance to host-directed antiviral drugs.
The articles describing original research, reviews, commentary, and clinical studies are invited on research, development, efficacy, formulation, and resistance of antiviral drugs against human RNA viruses such as, but not limited to, influenza virus, Sars coronavirus-2, Respiratory syncytial virus, HIV, and hepatitis C virus.
Keywords
- RNA viruses
- virus-directed antiviral drugs
- host-directed antiviral drugs
- Antiviral drug efficacy
- Antiviral drug resistance
All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisor for this Collection will not be handling the manuscripts (unless they are an Editorial Board member).
Please review the journal scope and author submission instructions prior to submitting a manuscript.
The deadline for submitting manuscripts is 31 July 2027.
Please contact Zhiyuan Zhang at zhiyuan.zhang@taylorandfrancis.com with any queries and discount codes regarding this Article Collection.
Guest Advisor
Prof. Matloob Husain is a career virologist with over 26 years of experience. Currently, his research group is studying the role of epigenetic protein modifications, like acetylation in influenza virus infection and pathogenesis.
Benefits of publishing open access within Taylor & Francis
Sustained readership
Publishing in an Article Collection ensures your research reaches a wide and engaged audience, driving long-term readership and citation impact.
Enhanced visibility
Gain recognition by showcasing your work in a trusted and reputable platform, amplifying your research’s visibility and influence.
Trends and methodologies
Connect with emerging topics and methodologies, positioning your research at the forefront of innovation and shaping the future of your field.
Support
Receive expert guidance at every stage of the publishing process from our experienced journal team, ensuring a seamless experience.
Network
Expand your professional network by collaborating with leading researchers from around the world, fostering interdisciplinary connections.
All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this Collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.